The recent executive order by President Trump concerning psychedelic medicines ignited a polarized response. While skeptics dismissed it as mere theatrics, advocates hailed it as a significant advancement. However, what is often overlooked in the American discourse is that Australia has been conducting a real-world experiment for over two years, yielding results that are transforming the care for veterans grappling with PTSD.
As the CEO of a pharmaceutical company that supplies clinical-grade MDMA in Australia, I have had a front-row seat to these developments. Australia became the first nation to permit psychiatrists to prescribe MDMA, marking a pivotal shift in how this substance is perceived. No longer a relic of the 1990s rave culture, MDMA is now recognized as a powerful tool for treating treatment-resistant PTSD based on clinical evidence.
The Right Direction
The executive order is a step in the right direction. It instructs the FDA to expedite the review of psychedelic medicines designated as Breakthrough Therapy, and it asks the DEA to prepare for rescheduling upon approval. Most importantly, it mandates collaboration between the Department of Health and Human Services, the FDA, and the Veterans Affairs to collect and analyze real-world evidence. This collaborative data is essential for transitioning a promising therapy from clinical trials to everyday clinical practice.
Australia’s approach over the past two years has focused on building a robust evidence base that American policymakers should closely observe.
Australia’s Groundbreaking Initiative
In November 2025, the Australian Department of Veterans’ Affairs (DVA) became the first government entity globally to fund MDMA-assisted psychotherapy for veterans suffering from PTSD. This decision was grounded in careful observation rather than speculation. The DVA monitored the Authorised Prescriber Scheme for over two years, documenting that treatments were conducted without significant adverse events. They also analyzed real-world outcomes, revealing that over half of the patients experienced substantial and lasting relief from their PTSD symptoms, despite having previously failed multiple standard treatment options.
Currently, Australian veterans can receive funding from the DVA for MDMA-assisted psychotherapy up to approximately $33,000 AUD. This comprehensive coverage includes the medication, psychiatrist fees, co-therapist costs, preparation sessions, dosing sessions, and subsequent integration work. For veterans who have struggled through various treatments without success, this funding can be life-changing. It can mean the difference between maintaining relationships, staying employed, or even surviving another year.
Addressing Challenges
While the Australian model is commendable, it is not without its flaws. The costs are significant, the number of qualified prescribers is limited, and many civilians remain unable to access these treatments due to pricing. Nevertheless, Australia’s initiative has succeeded in shifting the conversation from ideological debates to evidence-based discussions. The DVA did not wait for a cultural resolution on the merits of psychedelics; they focused on the clinical and safety data, ultimately prioritizing the urgent need to reduce veteran suicide rates.
A Template for the U.S.
The Australian experience provides a blueprint for how the United States can approach the issue. The executive order opens a pathway for the FDA to utilize a science-driven approval process, allowing the Veterans Affairs to actively engage in treating patients. This model emphasizes the importance of moving beyond ideological positions and instead focusing on empirical evidence to make informed decisions.
Moving Forward
In conclusion, Australia’s pioneering steps in MDMA therapy for veterans illustrate a pragmatic approach to mental health treatment. By prioritizing evidence over ideology, they have created a framework that the U.S. could emulate. As we look to the future, it is essential to embrace scientific data and real-world outcomes to ensure that veterans receive the care they desperately need and deserve.
Takeaways:
- Australia has successfully implemented MDMA-assisted psychotherapy for veterans, setting a global precedent.
- The DVA’s approach is grounded in empirical evidence, demonstrating significant relief for PTSD patients.
- The U.S. can learn from Australia’s model to prioritize data-driven decisions over ideological debates.
- Comprehensive funding for treatment can significantly impact veterans’ quality of life and mental health outcomes.
Read more → townhall.com